Clinical trialPhase 2Completed
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Multi-agent Low Dose Chemotherapy (Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, Irinotecan) Followed by Maintenance Olaparib and Pembrolizumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma.
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 29 September 2021
- Expected end
- 1 July 2026
- Enrollment
- 36 participants
- Sites
- 1
- Primary outcomes
- Progression-free Survival (PFS) Rate at 6 Months
- Sponsor
- Other
- Results posted
- 2026-11-04
- Last update
- 4 November 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to evaluate the safety and clinical activity of maintenance olaparib and pembrolizumab following multi-agent, low dose chemotherapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with untreated metastatic pancreatic ductal cancer.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Progression-free Survival (PFS) Rate at 6 Months [6 Months]. Number, Percent (95% Confidence Interval). GAX-CI Chemotherapy With Pembrolizumab and Olaparib (n=19): 21.05 (8.81 to 50.29).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants Experiencing Grade 3 or Above Drug-related Toxicities [Up to 34 months]. Count Of Participants, Participants. GAX-CI Chemotherapy With Pembrolizumab and Olaparib (n=36): 13.